First-in-Human Study of TAK-280 in Participants With Solid Tumors

Summary

The main aim of this study is to find out the safety, tolerability, and effect of TAK- 280 in participants with unresectable, locally advanced or metastatic cancer who have experienced treatment failure or are intolerant to standard therapies. Participants will be treated with TAK-280 for up to 14 treatment cycles. Each treatment cycle will be 28 days. After the last dose of study drug, participants will be followed up for survival every 12 weeks for a total of 48 weeks.

Timeline

Start

2022-04-21

Primary completion

2025-07-28

Completion

2025-07-28

Outcome

Outcome not reported

Stopped: “Terminated due to limited anti-cancer activity”

Drugs

Indications